TY - JOUR
T1 - HIVR4P 2016, Partnering for Prevention
T2 - Conference Summary and Highlights
AU - Shacklett, Barbara L.
AU - Derdeyn, Cynthia A.
AU - Folayan, Morenike Oluwatoyin
AU - Landovitz, Raphael J.
AU - Anthony, Colin
AU - Behrens, Anna Janina
AU - Hope, Thomas J.
AU - Landais, Elise
AU - Leal, Lorna
AU - Marrazzo, Jeanne M.
AU - Morris, Lynn
AU - Mugo, Nelly
AU - Ngure, Kenneth
AU - Noseda, Veronica
AU - Ranasinghe, Srinika
AU - Tully, Damien C.
AU - Voronin, Yegor
AU - Warren, Mitchell
AU - Wibmer, Constantinos Kurt
AU - Xie, Irene Y.
AU - Scarlatti, Gabriella
AU - Thyagarajan, Bargavi
N1 - Funding Information:
HIVR4P 2016 was made possible, in part, by the support of the American people through 1 R13 AI122959-01 from the National Institute of Allergy and Infectious Diseases (NIAID), and from the United States Agency for International Development (USAID).
Publisher Copyright:
© 2017 Barbara L. Shacklett t al.
PY - 2017/8
Y1 - 2017/8
N2 - HIV Research for Prevention: AIDS Vaccine, Microbicide, and ARV-based Prevention Science (HIVR4P) was built on a growing consensus that effective HIV prevention requires a combination of approaches and that understanding, analyzing, and debating the cross-cutting issues that impact prevention research are all essential to combat the global HIV/AIDS epidemic. To that end, the biennial HIVR4P conference is dedicated to all biomedical HIV prevention research approaches, including HIV vaccines, microbicides, pre-exposure prophylaxis, and treatment as prevention. The HIVR4P 2016 conference was held in Chicago, Illinois (USA), on October 17-21, and included more than 700 scientific presentations and 21 satellite sessions covering the latest and most promising advances across the HIV prevention research field. The theme "Partnering for Prevention" represented the conference's commitment to breaking down silos between research disciplines as well as between researchers, program developers, care providers, advocates, communities, and funders. Delegates spanning 42 countries attended the conference. One-third of those in attendance were early career investigators, which reflects a firm commitment to emerging researchers and ultimately to the goal of developing a sustainable scientific enterprise well into the future. This article presents a concise summary of highlights from the conference. For a more detailed account, one may find full abstracts, daily summaries, and webcasts on the conference website at hivr4p.org.
AB - HIV Research for Prevention: AIDS Vaccine, Microbicide, and ARV-based Prevention Science (HIVR4P) was built on a growing consensus that effective HIV prevention requires a combination of approaches and that understanding, analyzing, and debating the cross-cutting issues that impact prevention research are all essential to combat the global HIV/AIDS epidemic. To that end, the biennial HIVR4P conference is dedicated to all biomedical HIV prevention research approaches, including HIV vaccines, microbicides, pre-exposure prophylaxis, and treatment as prevention. The HIVR4P 2016 conference was held in Chicago, Illinois (USA), on October 17-21, and included more than 700 scientific presentations and 21 satellite sessions covering the latest and most promising advances across the HIV prevention research field. The theme "Partnering for Prevention" represented the conference's commitment to breaking down silos between research disciplines as well as between researchers, program developers, care providers, advocates, communities, and funders. Delegates spanning 42 countries attended the conference. One-third of those in attendance were early career investigators, which reflects a firm commitment to emerging researchers and ultimately to the goal of developing a sustainable scientific enterprise well into the future. This article presents a concise summary of highlights from the conference. For a more detailed account, one may find full abstracts, daily summaries, and webcasts on the conference website at hivr4p.org.
KW - HIV prevention
KW - PrEP
KW - R4P
KW - antibody
KW - microbicide
KW - vaccine
UR - http://www.scopus.com/inward/record.url?scp=85027027920&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85027027920&partnerID=8YFLogxK
U2 - 10.1089/aid.2017.0125
DO - 10.1089/aid.2017.0125
M3 - Article
C2 - 28649869
AN - SCOPUS:85027027920
SN - 0889-2229
VL - 33
SP - 749
EP - 759
JO - AIDS Research and Human Retroviruses
JF - AIDS Research and Human Retroviruses
IS - 8
ER -
